CALA insider filings

Calithera Biosciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-26. Screen CALA transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for CALA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Calithera Biosciences, Inc.

FiledFormInsiderReported transactionsSource
2023-05-264TAKEDA PHARMACEUTICAL CO LTD
Takeda Ventures, Inc. — 10% owner
Other (J): 1,000,000 (derivative)EDGAR
2023-01-314PAKIANATHAN DEEPIKA — DirectorSale (S): 120,161 @ $0.39 · Sale (S): 1,172 @ $0.39EDGAR
2023-01-254Sjogren Eric — SR. VP, DRUG DISCOVERYTax withholding (F): 279 @ $0.45EDGAR
2023-01-254Kuriakose Emil — CHIEF MEDICAL OFFICERTax withholding (F): 79 @ $0.45EDGAR
2023-01-254Molineaux Susan — PRESIDENT & CEO, DirectorTax withholding (F): 526 @ $0.45EDGAR
2023-01-254Wong Stephanie — See RemarksTax withholding (F): 317 @ $0.45EDGAR
2023-01-254Molineaux Christopher — SR. VP, DEVELOPMENTTax withholding (F): 217 @ $0.45EDGAR
2022-07-064TAKEDA PHARMACEUTICAL CO LTD — 10% owner
Takeda Ventures, Inc. — 10% owner
Other (J): 1,000,000 (derivative) @ $0 · Other (J): 1,000,000 (derivative) @ $0EDGAR
2022-06-034JONES SUZY — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034AGARWAL SUNIL — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034Garland J. Scott — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034Wise Blake — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034Orford Keith — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034Wolff Henry Ward — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-06-034PAKIANATHAN DEEPIKA — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2022-01-274Molineaux Susan — PRESIDENT & CEO, DirectorGrant/award (A): 597,475 (derivative) @ $0EDGAR
2022-01-274Wong Stephanie — See RemarksGrant/award (A): 215,000 (derivative) @ $0EDGAR
2022-01-274Ray Sumita — See RemarksGrant/award (A): 165,000 (derivative) @ $0EDGAR
2022-01-274Sjogren Eric — SR. VP, DRUG DISCOVERYGrant/award (A): 165,000 (derivative) @ $0EDGAR
2022-01-274Parlati Francesco — SR. VP, RESEARCHGrant/award (A): 165,000 (derivative) @ $0EDGAR
2022-01-274Molineaux Christopher — SR. VP, DEVELOPMENTGrant/award (A): 165,000 (derivative) @ $0EDGAR
2022-01-274Orford Keith — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-01-274Kuriakose Emil — CHIEF MEDICAL OFFICERGrant/award (A): 215,000 (derivative) @ $0EDGAR
2022-01-254Parlati Francesco — SR. VP, RESEARCHTax withholding (F): 4,794 @ $0.49EDGAR
2022-01-254Wong Stephanie — See RemarksTax withholding (F): 5,586 @ $0.49EDGAR
2022-01-254Sjogren Eric — SR. VP, DRUG DISCOVERYTax withholding (F): 4,794 @ $0.49EDGAR
2022-01-254Kuriakose Emil — CHIEF MEDICAL OFFICERTax withholding (F): 666 @ $0.49EDGAR
2022-01-064Parlati Francesco — SR. VP, RESEARCHTax withholding (F): 18,077 @ $0.66EDGAR
2022-01-064Kuriakose Emil — CHIEF MEDICAL OFFICERTax withholding (F): 3,855 @ $0.66EDGAR
2022-01-064Sjogren Eric — SR. VP, DRUG DISCOVERYTax withholding (F): 18,077 @ $0.66EDGAR
2022-01-064Wong Stephanie — See RemarksTax withholding (F): 18,077 @ $0.66EDGAR
2021-11-124Orford Keith — DirectorSale (S): 30,000 @ $0.86 · Sale (S): 48,190 @ $0.88EDGAR
2021-11-104Molineaux Susan — PRESIDENT & CEO, DirectorPurchase (P): 100,000 @ $0.85EDGAR
2021-11-104DRACHMAN JONATHAN G — DirectorPurchase (P): 200,000 @ $0.86EDGAR
2021-11-104Molineaux Christopher — SR. VP, DEVELOPMENTPurchase (P): 100,000 @ $0.85EDGAR
2021-11-094Orford Keith — DirectorGrant/award (A): 30,000 @ $0 · Sale (S): 51,810 @ $0.84EDGAR
2021-11-094Molineaux Christopher — SR. VP, DEVELOPMENTGrant/award (A): 12,000 @ $0EDGAR
2021-11-094Sjogren Eric — SR. VP, DRUG DISCOVERYGrant/award (A): 30,000 @ $0 · Tax withholding (F): 15,566 @ $0.87EDGAR
2021-11-094Wong Stephanie — See RemarksGrant/award (A): 30,000 @ $0 · Tax withholding (F): 15,566 @ $0.87EDGAR
2021-11-094Ray Sumita — See RemarksGrant/award (A): 12,000 @ $0EDGAR
2021-11-094Kuriakose Emil — CHIEF MEDICAL OFFICERGrant/award (A): 12,000 @ $0 · Tax withholding (F): 3,077 @ $0.87EDGAR
2021-11-094Parlati Francesco — SR. VP, RESEARCHGrant/award (A): 30,000 @ $0 · Tax withholding (F): 15,566 @ $0.87EDGAR
2021-10-294Sjogren Eric — SR. VP, DRUG DISCOVERYGrant/award (A): 90,000 @ $0 · Tax withholding (F): 45,965 @ $1.89EDGAR
2021-10-294Orford Keith — CHIEF MEDICAL OFFICERGrant/award (A): 90,000 @ $0EDGAR
2021-10-294Molineaux Christopher — SR. VP, DEVELOPMENTGrant/award (A): 36,000 @ $0EDGAR
2021-10-294Wong Stephanie — See RemarksGrant/award (A): 90,000 @ $0 · Tax withholding (F): 45,965 @ $1.89EDGAR
2021-10-294Ray Sumita — See RemarksGrant/award (A): 36,000 @ $0EDGAR
2021-10-294Parlati Francesco — SR. VP, RESEARCHGrant/award (A): 90,000 @ $0 · Tax withholding (F): 45,965 @ $1.89EDGAR
2021-06-144George Jean — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR
2021-06-144PAKIANATHAN DEEPIKA — DirectorGrant/award (A): 20,000 (derivative) @ $0EDGAR

Recent 8-K events — Calithera Biosciences, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-01-258-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-01-098-K?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2022-11-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-09-298-K1.02 — Termination of a Material Definitive AgreementEDGAR
2022-08-158-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-148-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-038-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2022-05-238-K1.01 — Entry into a Material Definitive Agreement
3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2022-05-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-04-128-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CALA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs